All In Biotech

Investigational drug · Phase 2

siplizumab

Also called: TCD601

Not approved by FDA. In 3 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Renal Transplant Failure and Rejection, Liver Transplantation, Renal Transplantation.

Phase 2

Last checked: Nov 20, 2026Latest source record: Nov 12, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations

Highest phase

Phase 2

Industry-sponsored trials

Phase 2 and 3 trials

3

2 still active

All registered trials

29

Any phase or sponsor naming "siplizumab"

First trial start

2022

Jun 29, 2022

Sponsors

Lead sponsors of its Phase 2 and 3 trials.

All registered trials by phase

Every ClinicalTrials.gov drug study naming "siplizumab", any sponsor or status.

Conditions studied

As listed on its trial records.

  • Renal Transplant Failure and Rejection
  • Liver Transplantation
  • Renal Transplantation

Approved drugs for the same conditions: Kidney and urology · Gastroenterology and liver

Largest trials

Live from ClinicalTrials.gov: studies naming "siplizumab" as an intervention, largest first.

All trials

Newest research

PubMed records naming it or its code names, newest first.

All 18 on PubMed

Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.